ES2175834T3 - Nuevos analogos tretaciclicos de camptotecinam, sus procedimientos de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. - Google Patents
Nuevos analogos tretaciclicos de camptotecinam, sus procedimientos de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.Info
- Publication number
- ES2175834T3 ES2175834T3 ES98962480T ES98962480T ES2175834T3 ES 2175834 T3 ES2175834 T3 ES 2175834T3 ES 98962480 T ES98962480 T ES 98962480T ES 98962480 T ES98962480 T ES 98962480T ES 2175834 T3 ES2175834 T3 ES 2175834T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- haloalkyl
- radical
- hydroxyalkyl
- naphthyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 20
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 125000001188 haloalkyl group Chemical group 0.000 abstract 14
- 125000001624 naphthyl group Chemical group 0.000 abstract 11
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 10
- 235000010290 biphenyl Nutrition 0.000 abstract 10
- 239000004305 biphenyl Substances 0.000 abstract 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 10
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 10
- -1 nitro, amino Chemical group 0.000 abstract 10
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 8
- 125000003282 alkyl amino group Chemical group 0.000 abstract 8
- 125000001475 halogen functional group Chemical group 0.000 abstract 8
- 125000001326 naphthylalkyl group Chemical group 0.000 abstract 7
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical group N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 abstract 1
- 125000004971 nitroalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Un compuesto, caracterizado porque dicho compuesto es de fórmula (I), **fórmula** en la forma racémica, enantiómera o cualquier combinación de estas formas, en la cual R1 representa un radical alquilo, alquenilo, alquinilo, haloalquilo, alcoxialquilo o alquiltioalquilo; R2, R3 y R4 representan independientemente un radical H, hidroxi, alcoxi, arilalcoxi, halo, haloalquilo, alquilo, alquenilo, ciano, cianoalquilo, nitro, nitroalquilo, amido, amidoalquilo, (CH2)mNR6R7, (CH2)mOR6, (CH2)mSR6, (CH2)mCO2R6, (CH2)mNR6C(O)R8, (CH2)mC(O)R8, (CH2)mOC(O)R8, O(CH2)mNR6R7, OC(O)NR6R7, OC(O)(CH2)mCO2R6, o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos de una a cuatro veces en el núcleo de fenilo, naftilo, antracilo, bifenilo o indenilo con uno o unos radicales escogidos entre un radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo, oR2 y R3, oR3 y R4, oR4 y R5, forman independientemente de forma conjunta una cadena de 3 ó 4 eslabones, en la que los elementos de la cadena se seleccionan entre el grupo constituido por CH, CH2, O,S, NoNR9; R5 representa un radical H, halo, haloalquilo, alquilo, alcoxi, alcoxialquilo, alquiltioalquilo, cicloalquilo, cicloalquilalquilo, ciano, cianoalquilo, alcanosulfonilalquilo, hidroxialquilo, nitro, (CH2)mC(O)R8, (CH2)mNR6C(O)R8, (CH2)mNR6R7, (CH2)mN(CH3)(CH2)nNR6R7, (CH2)mOC(O)R8, (CH2)mOC(O)NR6R7 o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos de una a cuatro veces en el núcleo de fenilo, naftilo, antracilo, bifenilo o indenilo con uno o unos radicales escogidos entre un radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; R6 y R7 representan, independientemente, H, un radical alquilo, hidroxialquilo, alquilaminoalquilo, aminoalquilo, cicloalquilo, cicloalquilalquilo, alquenilo, alcoxialquilo, haloalquilo, uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos de una a cuatro veces en el núcleo de fenilo, naftilo, antracilo, bifenilo o indenilo con uno o unos radicales escogidos entre un radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo, o bien, cuando las cadenas R6 y R7 están unidas a un mismo átomo de nitrógeno, R6 y R7 forman eventualmente de forma conjunta un grupo morfolino, piperazino o piperidino, estando eventualmente sustituido dicho grupo con uno o varios grupos escogidos entre radicales alquilo, fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; R8 representa unradical H, alquilo, hidroxialquilo, amino, alquilamino, alquilaminoalquilo, aminoalquilo, cicloalquilo, cicloalquilalquilo, alquenilo, alcoxi, alcoxialquilo, haloalquilo o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos de una a cuatro veces en el núcleo de fenilo, naftilo, antracilo, bifenilo o indenilo con uno o unos radicales escogidos entre un radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; R9 representa un radical H, alquilo, haloalquilo, o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos con uno de los grupos escogidos entre el radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; R10 representa un radical ciano, C(O)OR11, 1H-1,2,3,4-tetrazo-5-ilo o 1-alquil-1,2,3,4-tetrazo-5-ilo; R11 representa un radical H, alquilo, haloalquilo, hidroxialquilo, alquilcarboniloxialquilo, (CH2)P NR6R7, o uno de los radicales fenilo, naftilo, antracilo, bifenilo, indenilo, fenilalquilo, naftilalquilo, antracilalquilo, bifenilalquilo o indenilaquilo eventualmente sustituidos en el ciclo aromático con uno o varios grupos escogidos entre el radical alquilo, halo, nitro, amino, alquilamino, haloalquilo, hidroxialquilo, alcoxi o alcoxialquilo; m es un número entero comprendido entre 0 y 6; n es un número entero comprendido entre 1 y 4; p es un número entero comprendido entre 2 y 6; debiendo entenderse que: cada uno de los grupos alquilo que entran en las definiciones de los radicales anteriores es lineal o ramicado y comprende de 1 a 6 átomos de carbono; cada uno de los grupos alquenilo o alquinilo que entran en las definiciones de los radicales anteriores es lineal o ramificado y comprende de 2 a 6 átomos de carbono; y cada uno de los grupos cicloalquilo que entran en las definiciones de los radicales anteriores comprende de 3 a 7 átomos de carbono; o una sal farmacéuticamente aceptable de este último.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9716461A FR2772763B1 (fr) | 1997-12-24 | 1997-12-24 | Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2175834T3 true ES2175834T3 (es) | 2002-11-16 |
Family
ID=9515095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98962480T Expired - Lifetime ES2175834T3 (es) | 1997-12-24 | 1998-12-16 | Nuevos analogos tretaciclicos de camptotecinam, sus procedimientos de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6436951B1 (es) |
| EP (1) | EP1042323B1 (es) |
| JP (1) | JP2001527075A (es) |
| AR (1) | AR016440A1 (es) |
| AT (1) | ATE215951T1 (es) |
| AU (1) | AU749224B2 (es) |
| CA (1) | CA2315897C (es) |
| DE (1) | DE69804856T2 (es) |
| DK (1) | DK1042323T3 (es) |
| ES (1) | ES2175834T3 (es) |
| FR (1) | FR2772763B1 (es) |
| HU (1) | HUP0004628A3 (es) |
| IL (1) | IL136732A0 (es) |
| MY (1) | MY117585A (es) |
| NO (1) | NO316676B1 (es) |
| NZ (1) | NZ505339A (es) |
| PL (1) | PL193468B1 (es) |
| PT (1) | PT1042323E (es) |
| RU (1) | RU2220144C2 (es) |
| TW (1) | TW513429B (es) |
| WO (1) | WO1999033829A1 (es) |
| ZA (1) | ZA9811796B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003225642A1 (en) * | 2002-03-01 | 2003-09-16 | Fluorous Techonologies Inc | Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs |
| AU2002335472B8 (en) * | 2002-03-26 | 2007-12-20 | Banyu Pharmaceutical Co., Ltd. | Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent |
| EP1558614B1 (en) * | 2002-10-30 | 2010-09-01 | Merck Frosst Canada Ltd. | Pyridopyrrolizine and pyridoindolizine derivatives |
| DE112005002757T5 (de) * | 2004-12-08 | 2007-10-25 | Fuji Electric Holdings Co., Ltd., Kawasaki | Organische EL-Vorrichtung |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| JP5126707B2 (ja) * | 2007-04-23 | 2013-01-23 | 有機合成薬品工業株式会社 | α−ヒドロキシアシルピリジンの製造方法 |
| EA017648B1 (ru) | 2007-09-14 | 2013-02-28 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| RU2397984C1 (ru) * | 2009-03-05 | 2010-08-27 | Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ БЕНЗО[7,8]АЗОНИНО[5,4-b]ИНДОЛОВ, 7,9-ЭТЕНОАЗЕЦИНО[5,4-b]ИНДОЛОВ И 7,9-ЭТАНОАЗЕЦИНО[5,4-b]ИНДОЛОВ |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| HRP20131122T1 (hr) | 2009-05-12 | 2013-12-20 | Janssen Pharmaceuticals, Inc. | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| CN103588660B (zh) * | 2013-11-18 | 2016-06-01 | 中国医学科学院生物医学工程研究所 | 一种新型的酰基苯胺化合物及用途 |
| JP6219523B2 (ja) | 2013-12-13 | 2017-10-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼの阻害剤 |
| PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| DE69635560T2 (de) * | 1995-06-21 | 2006-08-17 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Camptothecinanaloge, Verfahren zur ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
-
1997
- 1997-12-24 FR FR9716461A patent/FR2772763B1/fr not_active Expired - Fee Related
-
1998
- 1998-12-14 TW TW087120746A patent/TW513429B/zh not_active IP Right Cessation
- 1998-12-15 MY MYPI98005659A patent/MY117585A/en unknown
- 1998-12-16 RU RU2000119731/04A patent/RU2220144C2/ru not_active IP Right Cessation
- 1998-12-16 PL PL98341288A patent/PL193468B1/pl not_active IP Right Cessation
- 1998-12-16 JP JP2000526510A patent/JP2001527075A/ja not_active Ceased
- 1998-12-16 AU AU17645/99A patent/AU749224B2/en not_active Ceased
- 1998-12-16 PT PT98962480T patent/PT1042323E/pt unknown
- 1998-12-16 WO PCT/FR1998/002751 patent/WO1999033829A1/fr not_active Ceased
- 1998-12-16 US US09/582,068 patent/US6436951B1/en not_active Expired - Fee Related
- 1998-12-16 EP EP98962480A patent/EP1042323B1/fr not_active Expired - Lifetime
- 1998-12-16 DE DE69804856T patent/DE69804856T2/de not_active Expired - Lifetime
- 1998-12-16 AT AT98962480T patent/ATE215951T1/de not_active IP Right Cessation
- 1998-12-16 DK DK98962480T patent/DK1042323T3/da active
- 1998-12-16 ES ES98962480T patent/ES2175834T3/es not_active Expired - Lifetime
- 1998-12-16 HU HU0004628A patent/HUP0004628A3/hu unknown
- 1998-12-16 NZ NZ505339A patent/NZ505339A/xx active IP Right Revival
- 1998-12-16 IL IL13673298A patent/IL136732A0/xx not_active IP Right Cessation
- 1998-12-16 CA CA002315897A patent/CA2315897C/fr not_active Expired - Fee Related
- 1998-12-21 AR ARP980106556A patent/AR016440A1/es unknown
- 1998-12-22 ZA ZA9811796A patent/ZA9811796B/xx unknown
-
2000
- 2000-06-23 NO NO20003314A patent/NO316676B1/no not_active IP Right Cessation
- 2000-12-12 US US09/734,167 patent/US6632946B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU749224B2 (en) | 2002-06-20 |
| ZA9811796B (en) | 1999-06-29 |
| NO316676B1 (no) | 2004-03-29 |
| NO20003314D0 (no) | 2000-06-23 |
| HUP0004628A1 (hu) | 2001-05-28 |
| US20010000521A1 (en) | 2001-04-26 |
| DE69804856D1 (de) | 2002-05-16 |
| PL193468B1 (pl) | 2007-02-28 |
| DK1042323T3 (da) | 2002-08-05 |
| WO1999033829A1 (fr) | 1999-07-08 |
| HUP0004628A3 (en) | 2001-11-28 |
| US6632946B2 (en) | 2003-10-14 |
| NO20003314L (no) | 2000-06-30 |
| EP1042323B1 (fr) | 2002-04-10 |
| PT1042323E (pt) | 2002-09-30 |
| CA2315897A1 (fr) | 1999-07-08 |
| JP2001527075A (ja) | 2001-12-25 |
| AR016440A1 (es) | 2001-07-04 |
| EP1042323A1 (fr) | 2000-10-11 |
| FR2772763B1 (fr) | 2004-01-23 |
| AU1764599A (en) | 1999-07-19 |
| FR2772763A1 (fr) | 1999-06-25 |
| DE69804856T2 (de) | 2002-11-07 |
| NZ505339A (en) | 2003-01-31 |
| MY117585A (en) | 2004-07-31 |
| CA2315897C (fr) | 2010-01-19 |
| US6436951B1 (en) | 2002-08-20 |
| TW513429B (en) | 2002-12-11 |
| ATE215951T1 (de) | 2002-04-15 |
| RU2220144C2 (ru) | 2003-12-27 |
| IL136732A0 (en) | 2001-06-14 |
| PL341288A1 (en) | 2001-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE44383T1 (de) | Bisacylphosphinoxide, ihre herstellung und verwendung. | |
| AR016440A1 (es) | Analogos tetraciclicos de camptotecina sus procedimientos de preparacion, productos intermediarios utilizados en dichos procedimientos, preparacion dedichos productos intermedios, uso de dichos analogos tetraciclicos para la preparacion de medicamentos y medicamentos y composiciones farmaceuticas qu | |
| CO4700576A1 (es) | Nuevos taxoides, su preparacion y las composiciones farmaceuticas que los contienen | |
| AR013494A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| AR004195A1 (es) | Nuevos derivados de la 5-0 desosaminil-6-0-metil-eritronolida a, su procedimiento de preparacion, compuestos intermediarios, metodo de aplicacionde los mismos para la preparacion de productos biologicamente activos. | |
| ES2062052T3 (es) | Derivados de cicloalcanos. | |
| ES2199696B1 (es) | Mezclas de estabilizantes. | |
| DK1204662T3 (da) | Azaindoler med serotoninreceptoraffinitet | |
| DK0664287T3 (da) | Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse | |
| ES8600246A1 (es) | Un metodo de preparar derivados de 4-quinolona | |
| ES2119874T3 (es) | Nuevos derivados de elipticina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| EA200300458A1 (ru) | Новые соединения аминотриазолона, способ их получения и фармацевтические композиции, содержащие их | |
| ATE176906T1 (de) | Benzolactam-derivate | |
| ZA851127B (en) | New 3-phenyl-2-propeneamine derivatives,their preparation and compositions containing them | |
| ATE27811T1 (de) | Ester von 2-adamantanonoxim. | |
| IT1255207B (it) | Composizioni farmaceutuche ad attivita' antiaggregante e vasodilatatrice | |
| TW330935B (en) | Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides | |
| CO4650113A1 (es) | Derivados de benzofenonhidrazona y el proceso para su produccion | |
| BG102429A (en) | Derivatives of 5-naphthalen-1-yl-1,3-dioxan, their preparation and usage as therapeutical means | |
| ES472591A1 (es) | Procedimiento para la obtencion de derivados de 1-fenileta- nolamina | |
| ES2115855T3 (es) | Nuevos derivados de 17-iminometilalquenil-5-beta-14-beta-androstanos y 17-iminoalquil-5-beta,14-beta-androstanos, un procedimiento para su produccion y las composiciones farmaceuticas que los incluyen. | |
| MX9303753A (es) | Dihidropiridinas anilladas y composiciones farmaceuticas que las contienen. | |
| ES8207543A1 (es) | Un procedimiento para la preparacion de nuevos derivados heterotriciclicos jaula. | |
| ES8602800A1 (es) | Un procedimiento compuesto de espiro 2h-1,4-benzodioxepin-3 (5h)4'-piperidina y -3'-pirrolidina | |
| ATE136036T1 (de) | Androst-4-en(4,5-b>-pyrrol-derivate und ein verfahren zu ihrer herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 1042323 Country of ref document: ES |